NEW
YORK, May 6, 2024 /PRNewswire/
-- Immunic, Inc. (Nasdaq: IMUX), a biotechnology
company developing a clinical pipeline of orally administered,
small molecule therapies for chronic inflammatory and autoimmune
diseases, today announced participation in the following investor
and scientific conferences in May:
- May 12-14 and 21-22: Bio€quity
Europe 2024. Jessica Breu, Vice President Investor Relations
and Communications at Immunic, will attend and host one-on-one
investor meetings at this conference taking place in San Sebastián,
Spain and virtually. To schedule a
meeting, please use the Bio€quity conference portal or contact
Jessica Breu at:
jessica.breu@imux.com.
- May 18-21: Digestive Disease
Week (DDW) 2024. Franziska Buriánek, M.D., Senior
Medical Director at Immunic, will present data from Immunic's phase
1b clinical trial of IMU-856, an
orally available and systemically acting small molecule modulator
that targets SIRT6 (Sirtuin 6), in patients with celiac disease, in
an oral presentation at this conference in Washington, DC. The presentation will be
accessible on the "Events and Presentations" section of Immunic's
website at: https://ir.imux.com/events-and-presentations.
- Presentation Title: First In Human Trial Of IMU-856, An
Orally Available Epigenetic Modulator Of Barrier Regeneration For
The Treatment Of Celiac Disease
- Abstract ID: 4025905
- Session Title: Since Sliced Bread: Best in Celiac
2024
- Session Type: Research Forum
- Session Date: Monday, May 20,
2024
- Session Time: 2:00 - 3:30 pm
EDT
- May 29 - June 1: The
Consortium of Multiple Sclerosis Centers (CMSC) 38th
Annual Meeting. Robert J. Fox,
M.D., Staff Neurologist, Mellen Center for Multiple Sclerosis,
Vice-Chair for Research, Neurological Institute, Cleveland Clinic,
Cleveland, Ohio will present
interim data from Immunic's phase 2 CALLIPER trial of lead asset,
nuclear receptor related 1 (Nurr1) activator, vidofludimus calcium
(IMU-838) at this meeting in Nashville,
TN. The poster presentation will be accessible on the
"Events and Presentations" section of Immunic's website at:
https://ir.imux.com/events-and-presentations.
- Poster Title: Impact of Vidofludimus Calcium on Serum
Neurofilament in Progressive MS: Assessment from the CALLIPER
Interim Analysis
- Abstract ID: 9651
- Poster Session Date: Thursday,
May 30, 2024
- Poster Session Time: 5:15 - 7:15
pm CDT (6:15 - 8:15 pm
EDT)
- May 30 - June 2: XXIII
National Congress of Neurology. Sonya Ivanova
Hristova-Chakmakova, M.D., Assistant Professor, Multiprofile
Hospital for Active Treatment in Neurology and Psychiatry «St.
Naum», Sofia, Bulgaria, will
present data from Immunic's phase 2 CALLIPER trial in an oral
presentation at this conference in Golden
Sands, Bulgaria. The
presentation will be accessible on the "Events and Presentations"
section of Immunic's website at:
https://ir.imux.com/events-and-presentations.
- Presentation Title: Impact of Vidofludimus Calcium
(VidoCa) on Serum Neurofilament Light Chain (NfL) Levels in
Patients with Progressive Multiple Sclerosis: Interim Data from the
CALLIPER Trial
- Poster ID: 201
- Poster Session: 2
- Date: Thursday, May 30,
2024
- Time: 2:00pm EEST
(7:00am EDT)
About Immunic, Inc.
Immunic, Inc. (Nasdaq: IMUX) is a biotechnology company developing
a clinical pipeline of orally administered, small molecule
therapies for chronic inflammatory and autoimmune diseases. The
company's lead development program, vidofludimus calcium (IMU-838),
is currently in phase 3 and phase 2 clinical trials for the
treatment of relapsing and progressive multiple sclerosis,
respectively, and has shown therapeutic activity in phase 2
clinical trials in patients suffering from relapsing-remitting
multiple sclerosis, progressive multiple sclerosis and
moderate-to-severe ulcerative colitis. Vidofludimus calcium
combines neuroprotective effects, through its mechanism as a
first-in-class nuclear receptor related 1 (Nurr1) activator, with
additional anti-inflammatory and anti-viral effects, by selectively
inhibiting the enzyme dihydroorotate dehydrogenase (DHODH).
IMU-856, which targets the protein Sirtuin 6 (SIRT6), is intended
to restore intestinal barrier function and regenerate bowel
epithelium, which could potentially be applicable in numerous
gastrointestinal diseases, such as celiac disease, for which it is
currently in preparations for a phase 2 clinical trial. IMU-381,
which currently is in preclinical testing, is a next generation
molecule being developed to specifically address the needs of
gastrointestinal diseases. For further information, please visit:
www.imux.com.
Cautionary Statement Regarding Forward-Looking
Statements
This press release contains "forward-looking statements" that
involve substantial risks and uncertainties for purposes of the
safe harbor provided by the Private Securities Litigation Reform
Act of 1995. All statements, other than statements of historical
facts, included in this press release regarding strategy, future
operations, future financial position, future revenue, projected
expenses, sufficiency of cash, expected timing, development and
results of clinical trials, prospects, plans and objectives of
management are forward-looking statements. Examples of such
statements include, but are not limited to, statements relating to
management's and employee's participation in investor and
scientific conferences. Immunic may not actually achieve the plans,
carry out the intentions or meet the expectations or projections
disclosed in the forward-looking statements and you should not
place undue reliance on these forward-looking statements. Such
statements are based on management's current expectations and
involve substantial risks and uncertainties. Actual results and
performance could differ materially from those projected in the
forward-looking statements as a result of many factors, including,
without limitation, the COVID-19 pandemic, increasing inflation,
impacts of the Ukraine –
Russia conflict and the conflict
in the Middle East on planned and
ongoing clinical trials, risks and uncertainties associated with
the ability to project future cash utilization and reserves needed
for contingent future liabilities and business operations, the
availability of sufficient financial and other resources to meet
business objectives and operational requirements, the fact that the
results of earlier preclinical studies and clinical trials may not
be predictive of future clinical trial results, the protection and
market exclusivity provided by Immunic's intellectual property,
risks related to the drug development and the regulatory approval
process and the impact of competitive products and technological
changes. A further list and descriptions of these risks,
uncertainties and other factors can be found in the section
captioned "Risk Factors," in the company's Annual Report on Form
10-K for the fiscal year ended December 31,
2023, filed with the SEC on February
22, 2024, and in the company's subsequent filings with the
Securities and Exchange Commission. Copies of these filings are
available online at www.sec.gov or ir.imux.com/sec-filings. Any
forward-looking statement made in this release speaks only as of
the date of this release. Immunic disclaims any intent or
obligation to update these forward-looking statements to reflect
events or circumstances that exist after the date on which they
were made. Immunic expressly disclaims all liability in respect to
actions taken or not taken based on any or all the contents of this
press release.
Contact Information
Immunic, Inc.
Jessica Breu
Vice President Investor Relations and Communications
+49 89 2080 477 09
jessica.breu@imux.com
US IR Contact
Rx Communications Group
Paula Schwartz
+1 917 633 7790
immunic@rxir.com
US Media Contact
KOGS Communication
Edna Kaplan
+1 617 974 8659
kaplan@kogspr.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/immunic-to-participate-in-investor-and-scientific-conferences-in-may-302135622.html
SOURCE Immunic, Inc.